Skip to Content


NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for cardiometabolic, viral, neuropathic, and neurodegenerative diseases, has a current portfolio of six drug candidates.

  • DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both non-alcoholic steatohepatitis (NASH) and type 2 diabetes (T2D). We intend to initiate a Phase 2a study in the first half of 2023 with the goal of establishing efficacy of DA-1241 in NASH and T2D.
  • DA-1726 is a novel oxyntomodulin analogue functioning as a dual agonist of GLP-1 and glucagon receptors (GLP1R/GCGR) for the treatment of NASH and obesity, that is to be administered once weekly subcutaneously. DA-1726 as a dual agonist of GLP1R/GCGR, leads to weight loss through reduced appetite and increased energy expenditure. We intend to advance DA-1726 through an Investigational New Drug application and initiation of human clinical trials in 2023.
  • ANA001 is a proprietary oral niclosamide formulation in development as a treatment for patients with moderate to severe COVID-19 (patients not requiring ventilators). Niclosamide is a potential oral antiviral and anti-inflammatory agent with a long history of use and a well-understood safety profile in humans. ANA001 is currently being studied in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the United States.
  • NB-01 is a proprietary botanical formulation composed of extracts from Dioscorea japonica and Dioscoreae nipponica. NB-01 has been shown in a Phase 2 study to significantly reduce pain symptoms associated with painful diabetic neuropathy (PDN), with a favorable safety profile. Due to the global COVID-19 crisis, a planned Phase 3 study was postponed. NeuroBo is also exploring a potential orphan drug indication targeting chronic pain for NB-01.
  • NB-02 novel proprietary botanical cocktail containing extracts from Morus alba L. and Poria cocos. The drug candidate is focused on the treatment of Alzheimer's disease and neurodegenerative diseases associated with the pathological dysfunction of tau proteins in the brain.
  • Gemcabene, which is currently being assessed as an acute indication for COVID-19 in combination with ANA001. Gemcabene was previously focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease, focused on orphan indications such as homozygous familial hypercholesterolemia, as well as NAFLD/NASH.

Financial Metrics

Stock Chart

Data Provided by Refinitiv. Minimum 15 minutes delayed.

View All